Tarsus Pharmaceuticals, Inc.
NASDAQ:TARSBiotechnology
+$0.29 today
- Market cap
- $3.74B
- Beta
- 0.51
- P/E (TTM)
- -55.9
- EPS (TTM)
- -$1.12
Volume 0.45M
Average 0.61M
TARS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Tarsus Pharmaceuticals, Inc.NASDAQ: TARS
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $668.33M (cash outflow) rose 5210.6% year over year, ahead of the +765.3% change in trailing-twelve-month net income. Sequentially, it rose 3502.7% from the prior quarter. Over 3 fiscal years it compounded at +2.3% a year.
Context
- Net income amounted to 14.7% of revenue in FY2025, down 48.4 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$640.95M (+865.0%) for the fiscal year ending Dec 2026, a step up from the -42.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$668.33M+3502.7% QoQ
- Last fiscal yearDec 2025
- -$66.42M-42.5% YoY
- LTMSep 2026
- -$702.23M+765.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5210.6% | +56.2% | -5154.4 pp |
| 1 year | -42.5% | +865.0% | +907.5 pp |
| 3-year CAGR | +2.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (66.42M) USD
- Year-over-year change
- +42.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (66.42M) | +42.5% |
| FY2024 | 2024-12-31 | (115.55M) | +15.0% |
| FY2023 | 2023-12-31 | (135.89M) | -118.9% |
| FY2022 | 2022-12-31 | (62.09M) | -349.1% |
| FY2021 | 2021-12-31 | (13.83M) | — |
Net Income vs competitors
How TARS compares with its peers on the latest reported figures
- TARS's LTM Sep 2026 net income of $702.23M is the largest of the 6 companies compared; the peer median is $14.92M.
- Its year-over-year change of +765.3% is the highest of 4, against a peer median of -31.0%.
- Net income amounts to 102.9% of revenue for TARS, versus a peer median of 27.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $702.23M | +765.3% | +2.3% | 102.9% | |
| LTM Jun 2026 | $28.52M | +130.6% | -62.7% | 6.1% | |
| LTM Mar 2026 | $17.83M | -73.0% | -9.9% | 48.0% | |
| LTM Mar 2026 | $14.96M | -31.0% | -28.5% | 5.6% | |
| LTM Jun 2024 | $14.92M | — | -25.7% | 227.4% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $3.84M | — | — | — |
| Peer median (excluding TARS) | $14.92M | -31.0% | -27.1% | 27.1% | |
Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.83M) | (62.09M) | (135.89M) | (115.55M) | (66.42M) |
| Depreciation & Amortization | 312K | 326K | 877K | 1.23M | 1.82M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.46M | 13.46M | 19.83M | 27.82M | 41.72M |
| Change in Working Capital | 1.37M | (951K) | 306K | 3.84M | 14.64M |
| Accounts Receivables | (73K) | (3.49M) | (14.13M) | (30.14M) | (39.05M) |
| Inventory | 0 | 3.49M | (3.11M) | (2.05M) | (1.75M) |
| Accounts Payables | 3.88M | 821K | 13.24M | 40.34M | 6.91M |
| Other Working Capital | (2.44M) | (1.77M) | 4.3M | (4.31M) | 48.53M |
| Other Non-Cash Items | 7.44M | 226K | (2.61M) | (360K) | (4.21M) |
| Operating Cash Flow | 3.75M | (49.03M) | (117.49M) | (83.03M) | (12.45M) |
| Capital Expenditures | (586K) | (506K) | (5.5M) | (1.57M) | (9.86M) |
| Acquisitions (Net) | 0 | 144.12M | 0 | 0 | 0 |
| Purchases of Investments | 0 | (149.44M) | (28.66M) | (265.63M) | (394.06M) |
| Sales of Investments | 0 | 5.32M | 174.77M | 73M | 361.8M |
| Other Investing Activities | 0 | (144.12M) | (4M) | (5M) | 0 |
| Investing Cash Flow | (586K) | (144.63M) | 140.6M | (199.2M) | (42.12M) |
| Debt Repayment | 0 | 19.13M | 10M | 39.6M | 0 |
| Common Stock Issued | 21K | 74.86M | 120.18M | 115.06M | 143.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 21K | 93.99M | 130.18M | 154.66M | 143.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 3.18M | (99.67M) | 153.29M | (127.57M) | 88.82M |
| Free Cash Flow | 3.16M | (49.54M) | (123M) | (84.59M) | (22.31M) |
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
Intrinsic Alpha fair value
Locked
Current Price
$75.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.